Anti-CYP2C9 antibody [EPR7340]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Cytochrome P450 2C9 often abbreviated as CYP2C9 is an enzyme belonging to the cytochrome P450 family known for its function in drug metabolism. CYP2C9 possesses an approximate mass of 55kDa and is found predominantly in the liver where it is highly expressed. As a heme-thiolate monooxygenase its mechanical action involves the oxidation of structurally diverse endogenous and exogenous compounds. These compounds include drugs steroids and fatty acids converting them into more water-soluble metabolites. Its role as a cytochrome P450 enzyme makes it an important target for CYP2C9 inhibitor assays used in various studies.

Biological function summary

CYP2C9 plays a significant role in drug metabolism and detoxification within the body including warfarin phenytoin and tolbutamide. It is a part of the extensive cytochrome P450 complex that is vital for the monooxygenation of various substrates. The enzyme acts on many drugs involved in anticoagulation anti-inflammatory processes and oral hypoglycemics facilitating their clearance from the body and influencing their pharmacokinetics and pharmacodynamics. Researchers conduct in vitro systems to test CYP2C9 activity and its inhibition contributing to drug safety evaluations.

Pathways

CYP2C9 integrates into the drug metabolism and lipid biosynthesis pathways. It works closely with other cytochrome P450 enzymes like CYP3A4 and CYP2C19 in metabolizing xenobiotics and endogenous substrates. In the arachidonic acid pathway CYP2C9 converts arachidonic acid to epoxyeicosatrienoic acids (EETs) which play roles in blood pressure regulation and inflammatory responses. These pathways highlight the importance of matching CYP2C9 and its related proteins to specific clinical outcomes particularly in the metabolism of various pharmaceutical agents.

Associated diseases and disorders

CYP2C9 exhibits significant associations with bleeding disorders related to warfarin metabolism and with phenytoin-induced toxicity. Genetic polymorphisms of CYP2C9 can result in altered enzyme activity leading to variable drug responses and adverse drug reactions particularly in medications with a narrow therapeutic index. The enzyme strongly interacts with VKORC1 in the context of warfarin therapy and mutations can cause issues in dose management. Understanding these interactions helps refine therapeutic strategies adjusting drug dosing to reduce risks of toxicity or therapeutic failure.